Camurus ABCAMRF 81 Net-Net Working Capital is $6.74 as of Mar. 2026. GuruFocus rates CAMRF with a GF Score™ of 81/100 and a GF Value™ of $83.32 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 860 Biotechnology companies, Camurus AB ranks worse than 66.16% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Camurus AB's Net-Net Working Capital for the quarter that ended in Mar. 2026 was $6.74.
The industry rank for Camurus AB's Net-Net Working Capital or its related term are showing as below:
CAMRF's Price-to-Net-Net-Working-Capital is ranked worse than 66.16% of 860
companies
in the Biotechnology industry
Industry Median: 5.5
vs CAMRF: 8.97
Camurus AB (OTCPK:CAMRF) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Camurus AB Net-Net Working Capital Related Terms
Camurus AB Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Camurus AB's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: Net-Net Working Capital Comparison
For the Biotechnology subindustry, Camurus AB's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Camurus AB's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $6.74 mean?
Camurus AB (CAMRF) has a Net-Net Working Capital of $6.74 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Camurus AB According to the industry distribution chart, Camurus AB ranks #569 out of 860 companies in the Biotechnology industry, placing it in the top 66.2%.
Is Camurus AB's Net-Net Working Capital too high?
Camurus AB's current Net-Net Working Capital is $6.74. The Biotechnology industry median Net-Net Working Capital is 5.50. Camurus AB's value of $6.74 is 22.5% above this industry median. Based on the distribution chart, Camurus AB ranks #569 out of 860 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Net-Net Working Capital compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #569 out of 860 companies for Net-Net Working Capital. This places Camurus AB in the lower half of its industry. The industry median Net-Net Working Capital is 5.50. Camurus AB's value of $6.74 is 22.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.50, based on 860 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Net-Net Working Capital of $6.74 is 22.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Camurus AB For the Biotechnology industry, the median Net-Net Working Capital is 5.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Net-Net Working Capital is $6.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $83.32, compared to a current price of $60.00 — trading 28% below its estimated fair value. The current Net-Net Working Capital is $6.74 and 22.5% above the Biotechnology industry median of 5.50. Camurus AB's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Net-Net Working Capital is $6.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $60.00 is trading 28% below its estimated GF Value™ of $83.32.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
Net-Net Working Capital: $6.74
GF Value™: $83.32 vs. price of $60.00 (28% below fair value)
Industry Position: 22.5% above the Biotechnology median (#569 of 860)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score
Get the complete analysis for CAMRF
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
